Advances in Lipid Testing and Management in Patients with Diabetes Mellitus

World Health Organization (WHO), 2009 Centers for Disease Control and Prevention (CDC), 2009 American Diabetes Association, 2009 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110:763], Circulation., 110, 227, 10.1161/01.CIR.0000133317.49796.0E Brunzell, 2008, Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation, J Am Coll Cardiol., 51, 1512, 10.1016/j.jacc.2008.02.034 American Diabetes Association, 2009, Standards of medical care in diabetes—2009, Diabetes Care., 32, S13, 10.2337/dc09-S013 Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 Mooradian, 2009, Dyslipidemia in type 2 diabetes mellitus, Nat Clin Pract Endocrinol Metab., 5, 150 Meigs, 1998, Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study, Ann Intern Med., 128, 524, 10.7326/0003-4819-128-7-199804010-00002 Howard, 1998, Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study, Metabolism., 47, 1174, 10.1016/S0026-0495(98)90319-5 Haffner, 1997, Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men, Diabetologia., 40, 711, 10.1007/s001250050738 Bays, 2006, Adiposopathy: why do adiposity and obesity cause metabolic disease?, Future Lipidol., 1, 389, 10.2217/17460875.1.4.389 Montecucco, 2008, Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability, Mediators Inflamm., 2008, 767623, 10.1155/2008/767623 Taskinen, 2003, Diabetic dyslipidaemia: from basic research to clinical practice, Diabetologia., 46, 733, 10.1007/s00125-003-1111-y Krauss, 2004, Dyslipidemia in type 2 diabetes, Med Clin North Am., 88, 897, 10.1016/j.mcna.2004.04.004 Del Pilar, 2005, Management of diabetic dyslipidemia, Endocrinol Metab Clin North Am., 34, 1, 10.1016/j.ecl.2005.01.001 Chahil, 2006, Diabetic dyslipidemia, Endocrinol Metab Clin North Am., 35, 491, 10.1016/j.ecl.2006.06.002 Mora, 2009, Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women, Clin Chem., 55, 888, 10.1373/clinchem.2008.117929 Cui, 2001, Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality, Arch Intern Med., 161, 1413, 10.1001/archinte.161.11.1413 Ridker, 2005, Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women, JAMA., 294, 326, 10.1001/jama.294.3.326 Bittner, 2002, Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI), Circulation., 106, 2537, 10.1161/01.CIR.0000038496.57570.06 Walldius, 2001, High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study, Lancet., 358, 2026, 10.1016/S0140-6736(01)07098-2 Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9 Sattar, 2004, Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study, Circulation., 110, 2687, 10.1161/01.CIR.0000145660.60487.94 Kathiresan, 2006, Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study, Circulation., 113, 20, 10.1161/CIRCULATIONAHA.105.567107 Pyörälä, 1997, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care. 1997;20:1048], Diabetes Care., 20, 614, 10.2337/diacare.20.4.614 Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med., 339, 1349, 10.1056/NEJM199811053391902 Gotto, 2000, Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), Circulation., 101, 477, 10.1161/01.CIR.101.5.477 Kastelein, 2008, (TNT Study Group; IDEAL Study Group). Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment, Circulation., 117, 3002, 10.1161/CIRCULATIONAHA.107.713438 Ballantyne, 2008, J Am Coll Cardiol., 52, 626, 10.1016/j.jacc.2008.04.052 Grundy, 2002, Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy, Circulation., 106, 2526, 10.1161/01.CIR.0000038419.53000.D6 Ballantyne, 2001, Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels, Am J Cardiol., 88, 265, 10.1016/S0002-9149(01)01638-1 Austin, 1988, Low-density lipoprotein subclass patterns and risk of myocardial infarction, JAMA., 260, 1917, 10.1001/jama.1988.03410130125037 Austin, 1990, Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk, Circulation., 82, 495, 10.1161/01.CIR.82.2.495 St-Pierre, 2001, Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease, Circulation., 104, 2295, 10.1161/hc4401.098490 Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis., 192, 211, 10.1016/j.atherosclerosis.2006.05.007 Campos, 2001, Low-density lipoprotein size, pravastatin treatment, and coronary events, JAMA., 286, 1468, 10.1001/jama.286.12.1468 O’Leary, 2002, Intima-media thickness: a tool for atherosclerosis imaging and event prediction, Am J Cardiol., 90, 18L, 10.1016/S0002-9149(02)02957-0 Lyons, 2006, Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness, Diabet Med., 23, 955, 10.1111/j.1464-5491.2006.01905.x Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation., 119, 931, 10.1161/CIRCULATIONAHA.108.816181 Howard, 2008, Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial, JAMA., 299, 1678, 10.1001/jama.299.14.1678 Davidson, 2005, Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations, Am J Cardiol., 96, 556, 10.1016/j.amjcard.2005.04.019 National Institutes of Health, National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity, 2000 Case, 2002, Impact of weight loss on the metabolic syndrome, Diabetes Obes Metab., 4, 407, 10.1046/j.1463-1326.2002.00236.x Pi-Sunyer, 2007, (Look AHEAD Research Group). Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial, Diabetes Care., 30, 1374, 10.2337/dc07-0048 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002, Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Mensink, 2003, Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, Am J Clin Nutr., 77, 1146, 10.1093/ajcn/77.5.1146 Dansinger, 2006, Low-carbohydrate or low-fat diets for the metabolic syndrome?, Curr Diab Rep., 6, 55, 10.1007/s11892-006-0053-4 LaMonte, 2005, Physical activity and diabetes prevention, J Appl Physiol., 99, 1205, 10.1152/japplphysiol.00193.2005 Harris, 1997, n-3 fatty acids and serum lipoproteins: human studies, Am J Clin Nutr., 65, 1645S, 10.1093/ajcn/65.5.1645S Harris, 1997, Safety and efficacy of Omacor in severe hypertriglyceridemia, J Cardiovasc Risk., 4, 385, 10.1097/00043798-199710000-00011 Sasaki, 2006, Statins: beneficial or adverse for glucose metabolism, J Atheroscler Thromb., 13, 123, 10.5551/jat.13.123 Coleman, 2008, The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials, Curr Med Res Opin., 24, 1359, 10.1185/030079908X292029 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 Soedamah-Muthu, 2003, The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease, Atherosclerosis, 167, 243, 10.1016/S0021-9150(02)00428-8 Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [published correction appears in N Engl J Med. 2005;353:1640], N Engl J Med., 353, 238, 10.1056/NEJMoa043545 Knopp, 2006, Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN), Diabetes Care., 29, 1478, 10.2337/dc05-2415 Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, 371, 117, 10.1016/S0140-6736(08)60104-X Ahmed, 2006, Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial, Eur Heart J., 27, 2323, 10.1093/eurheartj/ehl220 Shepherd, 2006, Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study, Diabetes Care., 29, 1220, 10.2337/dc05-2465 Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med., 359, 2195, 10.1056/NEJMoa0807646 Ridker, 2009, The JUPITER trial: results, controversies, and implications for prevention, Circ Cardiovasc Qual Outcomes., 2, 279, 10.1161/CIRCOUTCOMES.109.868299 Superko, 2004, Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I, Am J Cardiol., 94, 588, 10.1016/j.amjcard.2004.05.021 Carlson, 1989, Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid, J Intern Med., 226, 271, 10.1111/j.1365-2796.1989.tb01393.x Guyton, 2007, Safety considerations with niacin therapy, Am J Cardiol., 99, 22C, 10.1016/j.amjcard.2006.11.018 Elam, 2000, Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study; a randomized trial, JAMA, 284, 1263, 10.1001/jama.284.10.1263 Grundy, 2002, Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial, Arch Intern Med., 162, 1568, 10.1001/archinte.162.14.1568 Coronary Drug Project Research Group, 1975, Clofibrate and niacin in coronary heart disease, JAMA., 231, 360, 10.1001/jama.1975.03240160024021 Canner, 1986, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin, J Am Coll Cardiol., 8, 1245, 10.1016/S0735-1097(86)80293-5 Canner, 2005, Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project), Am J Cardiol., 95, 254, 10.1016/j.amjcard.2004.09.013 Staels, 1998, Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation., 98, 2088, 10.1161/01.CIR.98.19.2088 Muhlestein, 2006, The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study, J Am Coll Cardiol., 48, 396, 10.1016/j.jacc.2006.05.009 Manninen, 1992, Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment, Circulation., 85, 37, 10.1161/01.CIR.85.1.37 Rubins, 2002, Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), Arch Intern Med., 162, 2597, 10.1001/archinte.162.22.2597 2001, Lancet, 357, 905, 10.1016/S0140-6736(00)04209-4 Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [published corrections appear in Lancet. 2006;368: 1415 and Lancet. 2006;368:1420], Lancet., 366, 1849 Scott, 2009, Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Diabetes Care., 32, 493, 10.2337/dc08-1543 Chan, 2002, Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia, Diabetes., 51, 2377, 10.2337/diabetes.51.8.2377 Davidson, 2007, Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study, Clin Ther., 29, 1354, 10.1016/j.clinthera.2007.07.018 Marchioli, 2007, Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial, J Cardiovasc Med (Hagerstown)., 8, S34, 10.2459/01.JCM.0000289271.80180.b6 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico, 1999, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial [published corrections appear in Lancet. 2001;357:642 and Lancet. 2007;369:106], Lancet, 354, 447 Saito, 2008, Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS), Atherosclerosis., 200, 135, 10.1016/j.atherosclerosis.2008.06.003 Zieve, 2007, Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes, Clin Ther., 29, 74, 10.1016/j.clinthera.2007.01.003 Nambi, 2006, Combination therapy with statins and omega-3 fatty acids, Am J Cardiol, 98, 34i, 10.1016/j.amjcard.2005.12.025 Xydakis, 2002, Combination therapy for combined dyslipidemia, Am J Cardiol., 90, 21K, 10.1016/S0002-9149(02)02968-5 Goldberg, 2006, Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study [published correction appears in Mayo Clin Proc. 2007;82:387], Mayo Clin Proc., 81, 1579, 10.4065/81.12.1579 Ballantyne, 2008, Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study), Am J Cardiol., 101, 1428, 10.1016/j.amjcard.2008.02.092 Fleg, 2008, Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial, J Am Coll Cardiol., 52, 2198, 10.1016/j.jacc.2008.10.031 Ginsberg, 2007, Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 56i, 10.1016/j.amjcard.2007.03.024